1. Home
  2. ALLO vs GENC Comparison

ALLO vs GENC Comparison

Compare ALLO & GENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • GENC
  • Stock Information
  • Founded
  • ALLO 2017
  • GENC 1894
  • Country
  • ALLO United States
  • GENC United States
  • Employees
  • ALLO N/A
  • GENC N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • GENC Construction/Ag Equipment/Trucks
  • Sector
  • ALLO Health Care
  • GENC Industrials
  • Exchange
  • ALLO Nasdaq
  • GENC Nasdaq
  • Market Cap
  • ALLO 252.9M
  • GENC 240.4M
  • IPO Year
  • ALLO 2018
  • GENC N/A
  • Fundamental
  • Price
  • ALLO $1.43
  • GENC $14.12
  • Analyst Decision
  • ALLO Buy
  • GENC
  • Analyst Count
  • ALLO 12
  • GENC 0
  • Target Price
  • ALLO $8.80
  • GENC N/A
  • AVG Volume (30 Days)
  • ALLO 2.9M
  • GENC 29.4K
  • Earning Date
  • ALLO 11-06-2025
  • GENC 08-08-2025
  • Dividend Yield
  • ALLO N/A
  • GENC N/A
  • EPS Growth
  • ALLO N/A
  • GENC N/A
  • EPS
  • ALLO N/A
  • GENC 1.03
  • Revenue
  • ALLO N/A
  • GENC $117,527,000.00
  • Revenue This Year
  • ALLO N/A
  • GENC N/A
  • Revenue Next Year
  • ALLO $100.00
  • GENC N/A
  • P/E Ratio
  • ALLO N/A
  • GENC $13.76
  • Revenue Growth
  • ALLO N/A
  • GENC 3.90
  • 52 Week Low
  • ALLO $0.86
  • GENC $10.80
  • 52 Week High
  • ALLO $3.78
  • GENC $22.82
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 64.79
  • GENC 32.49
  • Support Level
  • ALLO $1.29
  • GENC $13.77
  • Resistance Level
  • ALLO $1.43
  • GENC $14.51
  • Average True Range (ATR)
  • ALLO 0.07
  • GENC 0.43
  • MACD
  • ALLO 0.02
  • GENC -0.08
  • Stochastic Oscillator
  • ALLO 78.17
  • GENC 5.55

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About GENC Gencor Industries Inc.

Gencor Industries Inc and its subsidiaries is a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company has one reporting segment, equipment for the highway construction industry. The firm's principal products include asphalt plants, combustion systems, hot mix asphalt plants, fluid heat transfer systems, and asphalt pavers.

Share on Social Networks: